– EU approves vaccine from Danish Bavarian Nordic
The Imvanex vaccine, already authorized once morest human smallpox, can also be used once morest monkeypox, the European Commission has decided.
The European Commission has approved the extension of a vaccine from the Bavarian Nordic pharmaceutical group once morest the spread of monkeypox, the Danish laboratory announced on Monday. At least 16,000 cases have been recorded worldwide.
The green light from Brussels follows that of the European regulator, the European Medicines Agency (EMA), which had given its agreement on Friday to the extension to monkeypox of the Imvanex vaccine, already authorized since 2013 in the European Union once morest human smallpox.
The green light from the Commission is valid in all member countries of the European Union as well as in Iceland, Liechtenstein and Norway, specifies the group.
Only licensed vaccine
The Imvanex vaccine is marketed as Jynneos in the United States, where it has been licensed once morest monkeypox since 2019. This makes it the only licensed vaccine for the prevention of the disease.
First detected in humans in 1970, monkeypox is less dangerous and contagious than its cousin human smallpox, eradicated in 1980. Contracted by close contact, it usually heals on its own following two or three weeks.
ATS
You found an error?Please let us know.